Rather, an accumulation of genetic, epigenetic and cellular events in canonical and non-canonical pathways within cancer cells and the TME drive a phenotype of decreased TGFβ responsiveness and the increased expression or activation of TGFβ ligands [17,86,87]. Here, TGFB1 is linked to cancer.